NASDAQ:GMDA • IL0011552663
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GAMIDA CELL LTD (GMDA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-01-29 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2023-12-05 | Needham | Reiterate | Buy -> Buy |
| 2023-11-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-11-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-28 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-08-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-15 | Needham | Reiterate | Buy -> Buy |
| 2023-06-30 | Needham | Reiterate | Buy -> Buy |
| 2023-05-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-19 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-05-16 | Needham | Reiterate | Buy -> Buy |
| 2023-05-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-04-20 | Needham | Maintains | Buy |
| 2023-04-19 | HC Wainwright & Co. | Maintains | Buy |
| 2023-04-18 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-28 | Oppenheimer | Maintains | Outperform |
| 2023-03-28 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-22 | Needham | Maintains | Buy |
| 2022-11-15 | Oppenheimer | Maintains | Outperform |
| 2022-09-29 | Needham | Maintains | Buy |
| 2021-11-16 | Needham | Maintains | Buy |
| 2021-11-16 | Oppenheimer | Maintains | Outperform |
| 2021-03-09 | Needham | Maintains | Buy |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.784M | 15.994M 796.52% | 188.78M 1,080.32% | 378.83M 100.67% | 741.74M 95.80% | 316.32M -57.35% | 1.543B 387.80% | 1.898B 23.01% | |||
| EBITDA YoY % growth | -86.74M -43.21% | -74.55M 14.05% | -70.619M 5.27% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -87.17M -43.07% | -74.99M 13.97% | -72.643M 3.13% | -71.832M 1.12% | 35.73M 149.74% | 167.79M 369.61% | 416.87M 148.45% | 684.93M 64.30% | 967.47M 41.25% | 1.21B 25.07% | |
| Operating Margin | N/A | N/A | -4,071.92% | -449.12% | 18.93% | 44.29% | 56.20% | 216.53% | 62.70% | 63.75% | |
| EPS YoY % growth | -1.52 6.17% | -1.24 18.42% | -0.63 49.19% | -0.57 9.37% | 0.17 130.37% | 0.92 429.41% | 2.24 144.44% | 3.65 62.73% | 5.13 40.50% | 6.40 24.65% |
All data in USD
| Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.14 49.00% | -0.15 52.29% | -0.15 -1,430.00% | -0.16 -295.25% |
| Revenue Q2Q % growth | 3.292M | 3.905M | 4.273M 537.76% | 5.23M 370.75% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -15.912M 18.73% | -16.878M 10.22% | -18.054M -0.08% | -18.654M -14.98% |
All data in USD
10 analysts have analysed GMDA and the average price target is 4.42 USD. This implies a price increase of 13416.73% is expected in the next year compared to the current price of 0.0327.
GAMIDA CELL LTD (GMDA) will report earnings on 2024-05-07, after the market close.
The consensus EPS estimate for the next earnings of GAMIDA CELL LTD (GMDA) is -0.14 USD and the consensus revenue estimate is 3.29M USD.
The consensus rating for GAMIDA CELL LTD (GMDA) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.